Imipenem/Cilastatine Hikma (Cilastatin Sodium, Imipenem Monohydrate)

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands, which leads to cell lysis. Cilastatin, co‑formulated with imipenem, blocks renal dehydropeptidase I, an enzyme that would otherwise degrade imipenem, thereby preserving its antibacterial activity in the bloodstream.

The dosage of Imipenem/Cilastatine Hikma is individualized by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local susceptibility patterns. Healthcare professionals determine the appropriate infusion rate, frequency, and duration according to established clinical guidelines.

Imipenem/cilastatin is classified as Pregnancy Category B, indicating that animal studies have not shown fetal risk, but there are no adequate controlled studies in pregnant women. It should be used during pregnancy only if clearly needed. Caution is advised during breastfeeding, as the drug may be excreted in milk; a risk‑benefit assessment should be performed by the prescriber.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed), and assist with import documentation.

Imipenem/cilastatin offers a broad spectrum of activity similar to other carbapenems such as meropenem or ertapenem, but it is distinguished by its co‑administration with cilastatin, which protects the drug from renal degradation, allowing higher plasma concentrations. Choice among carbapenems often depends on local resistance patterns, dosing convenience, and specific infection sites.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to use, the solution should be inspected for particulate matter and discoloration. If the product is removed from refrigeration, it should be used within the time frame specified in the product label.

Imipenem/Cilastatine Hikma is given as an intravenous infusion. The recommended infusion time varies with the dose and patient condition, typically ranging from 15 to 60 minutes. Administration should be performed by qualified healthcare personnel in a clinical setting, with appropriate monitoring for infusion‑related reactions.

Serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, Clostridioides difficile‑associated colitis, severe hypersensitivity reactions such as anaphylaxis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Prompt recognition and discontinuation of therapy are essential if any of these events occur.

Patients with a known hypersensitivity to imipenem, cilastatin, or any component of the formulation should not receive the drug. Caution is also advised for individuals with a history of seizures, severe renal impairment without dose adjustment, or those receiving concomitant medications that lower the seizure threshold.